GlassScriptPhysician profile
Jafar Mahmood
NPI 1154387165
$5,453.71
in general payments reported to CMS, 2019-2025
37 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $174 · 2021: $361 · 2022: $699 · 2023: $1,310 · 2024: $1,138 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,636 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,636.15 |
| Education | $117.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $729.39 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $535.80 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $486.96 | 2020-2025 | Krystexxa, Tavneos, Aranesp |
| Astrazeneca Pharmaceuticals LP | $461.47 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $446.16 | 2019-2025 | Veltassa |
| Horizon Therapeutics Plc | $363.89 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $281.51 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $251.65 | 2019-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $250.75 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $216.28 | 2021-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.12 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $141.67 | 2021-2024 | Lupkynis |
| Pfizer INC. | $114.38 | 2019 | |
| Ani Pharmaceuticals, INC. | $101.56 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $95.66 | 2022-2025 | Benlysta, Shingrix, Arexvy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| American Regent | $80.13 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $72.95 | 2024-2025 | Prevymis |
| Novartis Pharmaceuticals Corporation | $66.79 | 2024-2025 | |
| Baxter Healthcare | $66.69 | 2020-2023 | Renal - Pd |
| Ardelyx, INC. | $66.34 | 2024-2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $51.22 | 2025 | Empaveli |
| Mallinckrodt Enterprises LLC | $48.40 | 2019 | |
| Akebia Therapeutics INC | $42.26 | 2021-2024 | Vafseo, Auryxia |
| Veloxis Pharmaceuticals, INC. | $41.83 | 2020-2021 | |
| Genzyme Corporation | $24.91 | 2019 | |
| Scpharmaceuticals INC. | $24.71 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.39 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.03 | 2023 | Keveyis |
| Renalytix Ai, INC. | $21.44 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Cycle Pharmaceuticals INC | $21.27 | 2024 | Tiopronin |
| Curonix LLC | $20.66 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Lilly USA, LLC | $19.56 | 2023 | Jardiance |
| Medtronic, INC. | $16.63 | 2023 | |
| Chiesi USA, INC. | $15.52 | 2025 | Elfabrio |
| Daxor Corporation | $13.56 | 2024 | Bva-100 |
| Athena Bioscience, LLC | $12.62 | 2022 | |
| Spr Therapeutics, INC | $6.55 | 2025 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jafar Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.